• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Halozyme acquires Antares Pharma for $960M to create drug delivery company

April 13, 2022 By Sean Whooley

Halozyme AntaresHalozyme Therapeutics (Nasdaq:HALO) announced today that it will acquire Antares Pharma (Nasdaq:ATRS) for approximately $960 million.

Both companies’ boards of directors approved the transaction, which will see Halozyme acquire Antares for $5.60 per share in cash.

According to a news release, the business combination will create a leading drug delivery and specialty product company with Antares’ differentiated auto-injector platform business. The company offers a broad licensing opportunity and a commercial business with three proprietary commercial products.

Halozyme expects the acquisition to be immediately accretive to its 2022 revenue and non-GAAP earnings. The company also anticipates that it will accelerate growth through 2027 with multiple growth drivers beyond 2027.

“The addition of Antares, particularly with its best-in-class auto-injector platform and specialty commercial business, augments Halozyme’s strategy, further strengthens our position as a leading drug delivery company and extends our strategy to include specialty products,” Halozyme President and CEO Dr. Helen Torley said in the release. “The acquisition of Antares fits well with our previously discussed strategic priorities and provides substantial financial growth potential and disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies.”

Halozyme develops a proprietary enzyme — rHuPH20 — that forms the basis of its Enhanze technology, used to facilitate the delivery of injected drugs and fluids.

“We are pleased to have reached this agreement with Halozyme, as this transaction showcases the value of Antares’ highly complementary business, provides our shareholders with attractive and certain value, and brings together industry-leading expertise and drug delivery platforms to accelerate growth and create new opportunities,” Antares President and CEO Robert F. Apple said. “As we remain committed to continuing to serve our partners, I would like to thank our employees for their hard work and dedication to this mission. We look forward to working with the Halozyme team to complete the transaction and deliver best-in-class therapies and drug delivery solutions.”

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Antares Pharma, Halozyme Therapeutics

IN CASE YOU MISSED IT

  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS